Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization
about
Endorepellin, the angiostatic module of perlecan, interacts with both the α2β1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): a dual receptor antagonismTargeting extracellular domains D4 and D7 of vascular endothelial growth factor receptor 2 reveals allosteric receptor regulatory sitesSystems biology of the microvasculatureReceptor tyrosine kinase-mediated angiogenesisStructural and mechanistic insights into VEGF receptor 3 ligand binding and activationMolecular mechanisms and clinical applications of angiogenesisNormalization of the vasculature for treatment of cancer and other diseases.Structural basis of Tie2 activation and Tie2/Tie1 heterodimerization.Dimerization of Tie2 mediated by its membrane-proximal FNIII domains.Slit2N and Robo4 regulate lymphangiogenesis through the VEGF-C/VEGFR-3 pathwayMethodologies for the isolation of alternative binders with improved clinical potentiality over conventional antibodies.Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer.Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer.Inhibitory GH receptor extracellular domain monoclonal antibodies: three-dimensional epitope mappingVEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling.Affinity Maturation of Monoclonal Antibody 1E11 by Targeted Randomization in CDR3 Regions Optimizes Therapeutic Antibody Targeting of HER2-Positive Gastric CancerRecent progress in targeting cancer.Anti-Angiogenic Properties of BDDPM, a Bromophenol from Marine Red Alga Rhodomela confervoides, with Multi Receptor Tyrosine Kinase Inhibition Effects.Bevacizumab and breast cancer: what does the future hold?Endorepellin affects angiogenesis by antagonizing diverse vascular endothelial growth factor receptor 2 (VEGFR2)-evoked signaling pathways: transcriptional repression of hypoxia-inducible factor 1α and VEGFA and concurrent inhibition of nuclear factThe role of the VEGF-C/VEGFRs axis in tumor progression and therapy.A bispecific antibody against two different epitopes on hepatitis B surface antigen has potent hepatitis B virus neutralizing activity.Pulmonary lymphangiectasia resulting from vascular endothelial growth factor-C overexpression during a critical period.Preferential lymphatic growth in bronchus-associated lymphoid tissue in sustained lung inflammation.Emerging antibody combinations in oncology.Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look?The lymphatic vasculature in disease.Instigation of Notch signaling in the pathogenesis of Kaposi's sarcoma-associated herpesvirus and other human tumor viruses.Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancerLymphangiogenesis and lymphatic vessel remodelling in cancer.Antiangiogenesis therapy: an update after the first decade.Lymphangiogenic factors, mechanisms, and applications.Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer.Senescence from glioma stem cell differentiation promotes tumor growthBuilding the drains: the lymphatic vasculature in health and disease.Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer.The basis for the distinct biological activities of vascular endothelial growth factor receptor-1 ligands.Crosstalk between Stem and Progenitor Cellular Mediators with Special Emphasis on Vasculogenesis.New antibody to stop tumor angiogenesis and lymphatic spread by blocking receptor partnering.Vegfc acts through ERK to induce sprouting and differentiation of trunk lymphatic progenitors.
P2860
Q24303934-22E25E9E-2972-4A1E-9142-042DD19D0E17Q26822568-96DDB44B-04D7-4DFF-941E-F49CE486338FQ26850123-FF4E595A-BDFD-46DB-8DE0-D9453827F2A3Q27001612-C7AE6C89-E7B9-4472-AABE-BECB4961373EQ27679183-844F50DF-53A8-4309-8D8C-1FD755ACE6F1Q29547314-3C58C114-94D7-49C8-B636-7FDAEEA61EB8Q30471456-BB829D01-CC88-4CC3-8B05-4F34388F27A8Q33620110-CCF2ECF1-1FF2-4555-90A4-64B1FF96ABC7Q33620166-BEC09246-B7BD-4B77-874E-3B8C34E808D3Q34003819-3B432EB4-ADFE-4766-92F2-25EA074BC737Q34220190-7903D2AF-165B-4D74-B980-066852129418Q34266010-2CC31F03-FC49-4A72-AED6-F8005891871FQ34826155-E75963AF-E9C4-423E-B871-6977CF683D6BQ35590849-04653898-7EA5-41F1-86BB-91B1634A3268Q35682284-5EE942D4-E962-4C46-B90E-477B25064608Q35726067-D886754E-C727-4CFE-95F9-3F246079CF46Q35740782-76008146-8AB2-4C14-B92E-EE6592BC3224Q35814050-668D16A9-A113-401D-ADB0-ACA8E41844B8Q36298210-99D62F3F-7351-4AF8-B926-FCD29DA1FEBFQ36481790-E23B583E-64C4-49C4-BD35-CCF65A41D62CQ36589860-28516AD1-1BCA-4213-A7E1-9CC7D8AC5176Q37496579-E3E4B65C-97FB-4A19-A044-BCE2DCB17B11Q37672657-FE68C273-6245-4622-8F28-22D761405B12Q37734899-1DD703B2-3AEB-4575-A67D-DE4DD42BF307Q37893414-BC690ADC-C26E-4F2E-A81E-D295E8EFCECFQ37921797-92B1AACD-B230-4DBB-B66D-BDB58064FA11Q37953774-AE584D4E-2237-4ADC-AA3A-C6D5345E8F08Q38048861-8B44E925-FE73-4E13-9590-883FF3AB5B30Q38125964-156A7962-ED1B-4010-B2FB-D7897B227334Q38190359-CF0F647B-6EA8-4FDB-89F3-411730C65F4EQ38191586-F41AE318-B004-4CC6-8F0E-16FE8F8BF28EQ38192927-1D33E932-C13F-42A9-B7E9-5D1DE954F036Q38214511-4A5D6DDC-A775-4138-AB04-02A381331717Q38802705-928FF714-E769-4678-9206-0B0CC9A8F3EAQ38941223-3E56E2E0-A595-4E60-88EA-CE1F674C5732Q38948791-1F1355E2-D426-4B21-A0F4-95F04B0385DDQ39131192-76D49C97-B08F-49E0-AB01-E59F365AEE23Q39381566-7AAE4A33-B1D8-42F8-97CE-65F5CA0BF74CQ41932420-6F8830E9-19F2-4863-9C95-B1396549CA89Q42377401-3AF84964-0C2A-46B4-BCAB-E739DEEA6CD1
P2860
Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Effective suppression of vascu ...... ding and receptor dimerization
@ast
Effective suppression of vascu ...... ding and receptor dimerization
@en
Effective suppression of vascu ...... ding and receptor dimerization
@en-gb
Effective suppression of vascu ...... ding and receptor dimerization
@nl
type
label
Effective suppression of vascu ...... ding and receptor dimerization
@ast
Effective suppression of vascu ...... ding and receptor dimerization
@en
Effective suppression of vascu ...... ding and receptor dimerization
@en-gb
Effective suppression of vascu ...... ding and receptor dimerization
@nl
prefLabel
Effective suppression of vascu ...... ding and receptor dimerization
@ast
Effective suppression of vascu ...... ding and receptor dimerization
@en
Effective suppression of vascu ...... ding and receptor dimerization
@en-gb
Effective suppression of vascu ...... ding and receptor dimerization
@nl
P2093
P50
P1433
P1476
Effective suppression of vascu ...... ding and receptor dimerization
@en
P2093
Andrey Anisimov
Denis Tvorogov
Hanna Heloterä
Nisse Kalkkinen
Simonas Laurinavicius
Tanja Holopainen
P304
P356
10.1016/J.CCR.2010.11.001
P407
P50
P577
2010-12-14T00:00:00Z